OEA, a lipid that induces hypophagia and lowers fat mass, has been found to significantly increase GLP-1 levels within 15 minutes of supplementation. This discovery, made through a single-blind, placebo-controlled study in Brisbane, Australia, highlights the potential of OEA as a natural way to boost GLP-1 production. The study, funded by Saanroo, involved 43 overweight and obese participants who took either active capsules or placebo capsules after an overnight fast. The active capsules, containing 150mg of OEA, produced GLP-1 concentrations 20-25% higher than the placebo, with effects lasting even after the second meal. This finding is particularly intriguing given that OEA is typically produced in response to food intake, not fasting. The researchers suggest that OEA may augment enteroendocrine signaling and alter basal hormone secretion, potentially offering an alternative to GLP-1 receptor agonist medications, which are known to cause side effects. The study's results align with previous research showing that OEA can modulate the gut microbiome, leading to weight loss and improved intestinal health. This dual mechanism of action, affecting both the microbiome and GLP-1 production, positions OEA as a promising candidate for addressing metabolic health issues. Saanroo is now exploring further applications of OEA, including new health benefit claims for TRPTI, and plans to conduct additional studies on its effects on metabolic health and health span. The company's findings could redefine the science behind GLP-1, offering a natural and potentially safer approach to managing metabolic disorders.
